This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Optimizing IBS Management through Accurate Disease Assessment and Improved Treatment Selection

Optimizing IBS Management through Accurate Disease Assessment and Improved Treatment Selection



Time to Complete

1 hour


June 27, 2019


June 27, 2020
Add to Queue

Maximum Credits

1.00 / AMA PRA Category 1 CreditTM

Accredited Provider

Provided by Integrity Continuing Education, Inc.

Commercial Supporter

Supported by an educational grant from Salix Pharmaceuticals, Inc.

Program Description

Suboptimal irritable bowel syndrome (IBS) management frequently results from delayed diagnosis, underappreciation of disease impact on the part of providers, and inadequate symptom control despite therapy. There is a strong need for clinician education on strategies to promote more accurate disease assessment and improved treatment selection. In addition, clinicians also face challenges related to the need to keep pace with developments in understanding of the disease. For example, although recognition of the role of dysbiosis in IBS pathogenesis has grown significantly in recent years, the place of therapies targeting the gut microbiota has yet to be firmly established. Presently, several studies to address this issue are ongoing. As the results of these investigations become available, clinicians will require detailed education, along with expert guidance, to determine how to incorporate these findings into their therapeutic decision-making.

Intended Audience

This educational initiative has been designed for internal medicine physicians, nurse practitioners, physician assistants, and gastroenterology nurses involved in the management of patients with IBS.

Educational Objectives

Upon completion of this educational activity, participants should be able to:

  • Apply an approach to the diagnosis of IBS that is consistent with current evidence-based guidelines
  • Utilize best practices for the management of IBS, including accurate assessment of disease impact and selection of effective therapy
  • Describe current evidence in support of the gut microbiota as a therapeutic target in IBS treatment

Conflict Of Interest Disclosure Policy

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.


The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Brian E. Lacy, MD, PhD
Professor of Medicine
Senior Associate Consultant
Mayo Clinic, Jacksonville
Jacksonville, Florida

Dr. Lacy discloses the following:
Advisory Boards: Ironwood, Salix Pharmaceuticals, Inc., Shire
Consulting Fees: Neurogastrix, Urovant, Viver

Accredited Provider Disclosure

Integrity CE planners and managers have no relevant conflicts of interest to disclose.




AMA PRA Category 1 Credit(s)TM

Accreditation Statement

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education (CME) for physicians.

Designation Statement

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit(s)TM .  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Salix Pharmaceuticals, Inc. do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


The information provided in this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition.


There are no fees for participating and receiving CME credit for this activity. During the period of June 27, 2019 through June 27, 2020 participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pre-test
  • Study the educational activity
  • Complete the post-test and the evaluation form
A certificate will be issued only upon receipt of a completed activity evaluation form and a completed post-test with a score of 70% or higher. Please proceed with the activity until you have successfully passed the post-test, completed the evaluation and received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc., at (855) 835-4004 or

If you have any questions relating to your certificate or other issues with this activity, please contact

Privacy Policy


Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue